Hoth Therapeutics Files 8-K on Officer/Director Changes

Ticker: HOTH · Form: 8-K · Filed: 2025-08-22T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes

TL;DR

Hoth Therapeutics 8-K: Leadership changes and other events reported August 20, 2025.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers other events and financial statements and exhibits.

Why It Matters

This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in corporate leadership can introduce uncertainty regarding future strategy and performance.

Key Players & Entities

Hoth Therapeutics, Inc. (company) — Registrant
August 20, 2025 (date) — Date of earliest event reported

FAQ

What specific officer or director positions were affected by the changes reported in the 8-K?

The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but the specific names and roles are not detailed in the provided excerpt.

Are there any financial statements or exhibits included with this 8-K filing?

Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item information category.

What is the principal executive office address for Hoth Therapeutics, Inc.?

The principal executive offices are located at 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036.

What is the SIC code for Hoth Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Hoth Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

When was Hoth Therapeutics, Inc. incorporated and in which state?

Hoth Therapeutics, Inc. was incorporated in Nevada.

From the Filing

0001213900-25-079915.txt : 20250822 0001213900-25-079915.hdr.sgml : 20250822 20250822161538 ACCESSION NUMBER: 0001213900-25-079915 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250820 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250822 DATE AS OF CHANGE: 20250822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 251246476 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 8-K 1 ea0254112-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2025-08-20 2025-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) August 20, 2025   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   1177 Avenue of the Americas , 5th Floor , Suite 5066 New York , NY 10036 (Address of principal executive offices, including ZIP code)   ( 646 ) 756-2997 (Registrant’s telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers   On August 21, 2025, the board of directors (the “Board of Directors”) of Hoth Therapeutics, Inc. (the “Company”) approved the entry into an employment agreement (the “Employment Agreement”) with Robb Knie and on August 22, 2025 the Company ent